BioAtla (NASDAQ:BCAB) Releases Quarterly Earnings Results, Beats Expectations By $0.08 EPS

BioAtla (NASDAQ:BCAB) released its quarterly earnings data on Thursday. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.08, Zacks reports.

BioAtla Stock Down 4.9 %

BCAB traded down $0.02 during midday trading on Friday, hitting $0.37. The company had a trading volume of 1,443,415 shares, compared to its average volume of 994,354. The company has a market capitalization of $18.05 million, a price-to-earnings ratio of -0.22 and a beta of 1.19. The stock’s 50 day moving average price is $0.40 and its 200 day moving average price is $1.13. BioAtla has a 52 week low of $0.24 and a 52 week high of $4.02.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.